dc.contributor.advisor | Sharmin, Shahana | |
dc.contributor.author | Joya, Janifa Ferdous | |
dc.date.accessioned | 2025-01-13T04:04:01Z | |
dc.date.available | 2025-01-13T04:04:01Z | |
dc.date.copyright | ©2023 | |
dc.date.issued | 2023-09 | |
dc.identifier.other | ID 18346035 | |
dc.identifier.uri | http://hdl.handle.net/10361/25131 | |
dc.description | This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023. | en_US |
dc.description | Cataloged from PDF version of thesis. | |
dc.description | Includes bibliographical references (pages 49-54). | |
dc.description.abstract | Cancer is a dangerous disease that has plagued humanity for centuries, ranking asathe second
leadingacauseaofaglobal mortality. Ina2020, nearly 20 million lives were lost to cancer, with
breast cancer (BC) being the most common type. Understanding the risk factors for developing
BC, such as family history, is crucial for improving survival rates. There are various treatment
methods available for BC, including the use of docetaxel with monoclonal antibodies Pertuzumab
& Trastuzumab, which target the overexpressed the human epidermal growth factor
receptor 2 (HER2) gene in HER2-positive breast tumors. These antibodies have significantly
changed the therapeutic strategy for the human epidermal growth factor receptor 2(HER2)-
positive breast cancer. However, while patient results have improved, the number of people
benefiting from this medication. This paper aims to explore all available BC treatments & propose
a model of the synergistic effects of trastuzumab & pertuzumab, critically analyzing findings
& hypotheses related to their combined activity. | en_US |
dc.description.statementofresponsibility | Janifa Ferdous Joya | |
dc.format.extent | 66 pages | |
dc.language.iso | en | en_US |
dc.publisher | Brac University | en_US |
dc.rights | Brac University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. | |
dc.subject | Breast cancer | en_US |
dc.subject | Cancer therapy | en_US |
dc.subject | Pertuzumab | en_US |
dc.subject | Trastuzumab | en_US |
dc.subject | HER2 | en_US |
dc.subject | HER family receptors | en_US |
dc.subject | Risk factors | en_US |
dc.subject.lcsh | Breast--Cancer--Genetic aspects--Chemotherapy. | |
dc.subject.lcsh | HER-2 gene. | |
dc.subject.lcsh | HER-2 protein. | |
dc.subject.lcsh | Cancer--Gene therapy. | |
dc.title | Trastuzumab & Pertuzumab in the fight against breast cancer: mechanisms, significance, & future aspects | en_US |
dc.type | Thesis | en_US |
dc.contributor.department | School of Pharmacy, Brac University | |
dc.description.degree | B. Pharmacy | |